An update on the pathology and clinical management of gouty arthritis

被引:31
作者
Gonzalez, Emilio B. [1 ]
机构
[1] UTMB, Div Rheumatol, Dept Med, Galveston, TX 77555 USA
关键词
Chronic diseases; Gouty arthritis; Inflammation; Pathophysiology; URATE-LOWERING THERAPY; PARALLEL-GROUP; ACUTE FLARES; DOUBLE-BLIND; URIC-ACID; PHASE-II; HYPERURICEMIA; PEGLOTICASE; PREVALENCE; FEBUXOSTAT;
D O I
10.1007/s10067-011-1877-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gouty arthritis is an inflammatory condition associated with debilitating clinical symptoms, functional impairments, and a substantial impact on quality of life. This condition is initially triggered by the deposition of monosodium urate crystals into the joint space. This causes an inflammatory cascade resulting in the secretion of several proinflammatory cytokines and neutrophil recruitment into the joint. While generally effective, currently available agents are associated with a number of adverse events and contraindications that complicate their use. Based on our increased understanding of the inflammatory pathogenesis of gouty arthritis, several new agents are under development that may provide increased efficacy and reduced toxicity.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 36 条
  • [1] Resolution of gouty tophi after twelve weeks of pegloticase treatment
    Baraf, Herbert S. B.
    Matsumoto, Alan K.
    Maroli, Allan N.
    Waltrip, Royce W., II
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3632 - 3634
  • [2] Febuxostat compared with allopurinol in patients with hyperuricemia and gout
    Becker, MA
    Schumacher, HR
    Wortmann, RL
    MacDonald, PA
    Eustace, D
    Palo, WA
    Streit, J
    Joseph-Ridge, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) : 2450 - 2461
  • [3] Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy
    Becker, Michael A.
    MacDonald, Patricia A.
    Hunt, Barbara J.
    Lademacher, Christopher
    joseph-Ridge, Nancy
    [J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2008, 27 (6-7) : 585 - 591
  • [4] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase
    Becker, Michael A.
    Schumacher, H. Ralph, Jr.
    Wortmann, Robert L.
    MacDonald, Patricia A.
    Palo, William A.
    Eustace, Denise
    Vernillet, Laurent
    Joseph-Ridge, Nancy
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (03): : 916 - 923
  • [5] The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
    Becker, Michael A.
    Schumacher, H. Ralph
    Espinoza, Luis R.
    Wells, Alvin F.
    MacDonald, Patricia
    Lloyd, Eric
    Lademacher, Christopher
    [J]. ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)
  • [6] Becker MA, 2010, J FAM PRACTICE, V59, pS1
  • [7] Anakinra's Efficacy is Variable in Refractory Gout: Report of Ten Cases
    Chen, Kun
    Fields, Theodore
    Mancuso, Carol A.
    Bass, Anne R.
    Vasanth, Lisa
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 40 (03) : 210 - 214
  • [8] Alcohol intake and risk of incident gout in men: a prospective study
    Choi, HK
    Atkinson, K
    Karlson, EW
    Willett, W
    Curhan, G
    [J]. LANCET, 2004, 363 (9417) : 1277 - 1281
  • [9] Purine-rich foods, dairy and protein intake, and the risk of gout in men
    Choi, HK
    Atkinson, K
    Karlson, EW
    Willett, W
    Curhan, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1093 - 1103
  • [10] Pathogenesis of gout
    Choi, HK
    Mount, DB
    Reginato, AM
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (07) : 499 - 516